Are you Dr. Gheuens?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 5 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
E/Cls-1017
Boston, MA 02215Phone+1 617-735-4468Fax+1 617-735-4527
Summary
- Dr. Sarah Gheuens, MD is a neurologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is an Instructor at Beth Israel Deaconess Medical Center.
Education & Training
Vrije Universiteit BrusselsClass of 2004
Certifications & Licensure
MA State Medical License 2011 - 2025
Publications & Presentations
PubMed
- 1 citationsSafety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.Modupe Idowu, Lucas Otieno, Bogdan Dumitriu, Clarisse L C Lobo, Swee Lay Thein
The Lancet. Haematology. 2025-01-01 - 4 citationsEarly-onset reduced bone mineral density in patients with pyruvate kinase deficiency.Hanny Al-Samkari, Rachael F Grace, Andreas Glenthøj, Oliver Andres, Wilma Barcellini
American Journal of Hematology. 2023-03-01 - 19 citationsMitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.Andreas Glenthøj, Eduard J van Beers, Hanny Al-Samkari, Vip Viprakasit, Kevin H M Kuo
The Lancet. Haematology. 2022-10-01
Press Mentions
Mitapivat Under Review for Alpha- and Beta-ThalassemiaJanuary 13th, 2025- Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on MitapivatDecember 8th, 2024
- Centogene and Agios Expand Rare Blood Disease PartnershipNovember 5th, 2021
- Join now to see all
